Medifast (MED) Misses Q1 EPS by 84c, Guidance Misses
Tweet
Share
E-mail
Get Alerts MED Hot Sheet
Price: $12.16 -3.72%
Revenue Growth %: -24.3%
Financial Fact:
Cost of sales: 16.42M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -24.3%
Financial Fact:
Cost of sales: 16.42M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Medifast (NYSE: MED) reported Q1 EPS of $0.66, $0.84 worse than the analyst estimate of $1.50. Revenue for the quarter came in at $174.7 million versus the consensus estimate of $205.79 million.
GUIDANCE:
Medifast sees Q2 2024 EPS of $0.05-$0.40, versus the consensus of $0.67. Medifast sees Q2 2024 revenue of $150-170 million, versus the consensus of $175.1 million.
For earnings history and earnings-related data on Medifast (MED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
- BMO Capital Starts Carter's (CRI) at Outperform
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
